Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TruScreen Group Ltd. ( (NZ:TRU) ) just unveiled an announcement.
TruScreen Group has partnered with Lagos State University Teaching Hospital and Lagos State University College of Medicine in Nigeria on a Bill & Melinda Gates Foundation grant application to support cost-disruptive cervical cancer screening. The proposed two-year study would use TruScreen’s AI-enabled device in a same-visit “screen-and-treat” model in rural clinics, targeting 500 to 1,500 women in a country with the highest cervical cancer burden in Africa.
The collaboration leverages TruScreen’s portability and real-time diagnostics, which do not require lab infrastructure or specialist personnel, aligning with the Gates Foundation’s focus on scalable, low-resource tools. If funded, the project could generate the first West African validation dataset for TruScreen and potentially influence Nigerian national screening guidelines, strengthening the company’s positioning in global public health markets.
More about TruScreen Group Ltd.
TruScreen Group Ltd. is a medical device company focused on cervical cancer screening, offering an AI-enabled real-time device that detects abnormalities in cervical tissue without the need for laboratory-based cytology. Its TruScreen Ultra device is approved or registered in multiple markets including China, Australia, the UK, Mexico, Russia, Saudi Arabia, Vietnam and others, and is supported by distributors in 29 countries and growing usage in emerging markets.
Average Trading Volume: 512,231
Technical Sentiment Signal: Sell
Current Market Cap: N$12.7M
For an in-depth examination of TRU stock, go to TipRanks’ Overview page.